In the last trading session, 2.13 million shares of the Monte Rosa Therapeutics Inc (NASDAQ:GLUE) were traded, and its beta was 1.29. Most recently the company’s share price was $5.80, and it changed around -$1.26 or -17.85% from the last close, which brings the market valuation of the company to $356.76M. GLUE currently trades at a discount to its 52-week high of $12.40, offering almost -113.79% off that amount. The share price’s 52-week low was $3.21, which indicates that the current value has risen by an impressive 44.66% since then. We note from Monte Rosa Therapeutics Inc’s average daily trading volume that its 10-day average is 0.92 million shares, with the 3-month average coming to 722.49K.
Monte Rosa Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended GLUE as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Monte Rosa Therapeutics Inc is expected to report earnings per share of -0.32 for the current quarter.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Instantly GLUE has showed a red trend with a performance of -17.85% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.31 on recent trading dayincreased the stock’s daily price by 20.66%. The company’s shares are currently down -16.43% year-to-date, but still down -7.50% over the last five days. On the other hand, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) is -12.52% down in the 30-day period. We can see from the shorts that 8.04 million shares have been sold at a short interest cover period of 17.6 day(s).
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
The year-over-year growth rate is expected to be -9.48%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 13.57M in revenue for the current quarter. 6 analysts expect Monte Rosa Therapeutics Inc to make 13.57M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.06M and 4.7M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 1,175.06%. Forecasts for the next quarter put sales growth at 188.96%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -41.09%. Monte Rosa Therapeutics Inc earnings are expected to increase by -45.70% in 2025, but the outlook is negative -22.13% per year for the next five years.
GLUE Dividends
Monte Rosa Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-19.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.70% of Monte Rosa Therapeutics Inc shares, and 102.30% of them are in the hands of institutional investors. The stock currently has a share float of 103.02%. Monte Rosa Therapeutics Inc stock is held by 148.0 institutions, with NEA MANAGEMENT COMPANY, LLC being the largest institutional investor. By 2024-06-30, it held 10.7986% of the shares, which is about 7.69 million shares worth $28.77 million.
PRICE T ROWE ASSOCIATES INC /MD/, with 9.9368% or 5.98 million shares worth $22.36 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
